To our knowledge, the first study carried out on AF anticancer activity on lymphoma cell lines was published by Cox et al.67They demonstrated that AF treatment activated apoptotic signaling through a Bcl‐2 homologous antagonist/(Bax/Bak)‐dependent mechanism associated to TrxR inhibition and peroxiredoxin3 (Prx3) oxidation in Jurkat T‐lymphoma and U937 monocytic cell lines. The gene discussed is BCL2; the disease is lymphoma.